Key facts
- It has raised $24.8M.
- Notable investors include MassChallenge, Venture Kick, Ecole Polytechnique Federale de Lausanne, Innosuisse, Zürcher Kantonalbank — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Resistell
- ·The full record, as it builds
Funding rounds
No funding rounds for Resistell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Resistell
Developer of a proprietary Antibiotic Susceptibility Testing (AST) platform designed to provide rapid diagnostic results. The company's platform offers nanomotion analysis technology for phenotypic testing to detect the movement caused by living bacterial cells to determine bacterial resistance to antibiotics, enabling clients using diagnostic microbiology and microbial kinetics to improve antibiotic resistance testing with faster results, offering a new rapid AST gold standard.
- Sector
- Healthcare
- HQ
- Muttenz, Switzerland
- Founded
- 2017
- Employees
- 19
- Website
- resistell.com/
- Ownership
- Privately Held (backing)
Resistell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Resistell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Resistell in its N-PORT filings yet. We sweep new filings monthly.